Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 1-year history of chronic migraine (CM) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3), 2018~* Age of the participant at the time of migraine onset \< 50 years~* Confirmation of headache/migraine headache day frequency as follows:~  * History of, on average, ≥ 15 headache days per month in the 3 months prior to Visit 1 in the opinion of the investigator AND~ * \>=15 headache days during the 4-week screening/baseline period per the electronic diary (eDiary) AND~ * \>=8 days during the 4-week screening/baseline period that qualify as being a migraine day per the eDiary~* Participants must be using a medically acceptable and effective method of birth control during the course of the entire study~Exclusion Criteria:~* Has a history of migraine, accompanied by diplopia or decreased level of consciousness, or retinal migraine~* Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy~* History of an inadequate response to \> 4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine~* Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating. Women of childbearing potential must have a negative urine pregnancy test at Visit 1 and Visit 2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received atogepant-matching placebo tablets, orally, twice daily (BID) for 12 weeks in a double-blind (DB) treatment period.
- Atogepant 30 mg BID (Type: ACTIVE_COMPARATOR): Participants received atogepant 30 mg tablet, orally, BID and atogepant-matching placebo tablets orally, BID for up to 12 weeks in a DB treatment period.
- Atogepant 60 mg QD (Type: ACTIVE_COMPARATOR): Participants received atogepant 60 mg, orally, once daily (QD) along with atogepant-matching placebo 30 mg as morning dose followed by atogepant-matching placebo 30 mg and 60 mg as evening doses for up to 12 weeks in a DB treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).